Is the ideal anticoagulant a myth?

Expert Review of Clinical Pharmacology

Volumn 5, Issue 3, 2012, Pages 231-236

  Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

anticoagulants; anticoagulation; clinical pharmacology; modeling; multiscale pharmacology model; pharmacodynamics; pharmacokinetics

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; DABIGATRAN; FIBRINOGEN; MELAGATRAN; PROTHROMBIN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG TARGETING; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT CARE; REVIEW; STROKE; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 84861443924     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.18     Document Type: Review

References (20)

1. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/anhtithrombotics: for and against? Clin. Chem. Lab. Med. 49(5), 755-757 (2011
2. Holford NHG. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Br. J. Clin. Pharmacol. 48, 9-13 (1999
3. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rovaroxaban: their suitability and limitations. Ther. Drug Monit. 32(6), 673-679 (2010
4. Bereznicki LRE, Peterson GM. New antighrombotics for atrial fibrillation. Cardiovasc. Ther. 28(5), 278-386 (2010
5. Ott I. Inhibitors of the initiation of coagulation. Br. J. Clin. Pharmacol. 72(4), 547-552 (2011
6. Wajima T, Isbister GK, Duffull SB. A comprehensive model for the humoral coagulation network in humans. Clin. Pharmacol. Ther. 86(3), 290-298 (2009
7. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am. J. Hematol. 85(3), 185-187 (2010
8. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019-1026 (2003
9. Kurnik D, Loebstein HH, Gak E, Almog S. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 10(12), 1955-1965 (2009
10. Harenberg J, Wehling M. Future anticoagulant therapy. Cardiovasc. Ther. 29(5), 291-300 (2011
11. Huo MH. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Thromb. Haemost. 106(1), 45-57 (2011
12. Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet. 47(3), 203-216 (2008
13. Mueck W, Borris LC, Dahl OE et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention ofvenous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost. 100(3), 453-461 (2008
14. Hamberg AK, Dahl ML, Barban M et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther. 81(4), 529-538 (2007
15. Lane S, Al-Zubiedi S, Hatch E et al. The population pharmacokinetics of R-and S-warfarin: effect of genetic and clinical factors. Br. J. Clin. Pharmacol. 73(1), 66-76 (2012
16. Hamberg AK, Wadelius M, Lindh JD et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1 and age. Clin. Pharmacol. Ther. 87(6), 727-734 (2010
17. Troconiz I, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement. J. Clin. Pharmacol. 47(3), 371-382 (2007
18. Akimoto K, Klinkhardt U, Zeiher A, Niethammer M, Harder S. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. J. Clin. Pharmacol. 51(6), 805-818 (2011
19. Bååthe S, Hamrén B, Karlsson MO et al. Population pharmacokinetics of melagatran, the active form of the direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. Clin. Pharmacokinet. 45(8), 803-819 (2006
20. Eastham RD, Slade RR. Bleeding, clotting and transfusion. Clinical Haematology (7th Edition). Butterworth Heinemann, Oxford, UK, 131-216 (1992)